Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Modi, Shanu, Saura, Cristina, Yamashita, Toshinari, Park, Yeon Hee, Kim, Sung-Bae, Tamura, Kenji, Andre, Fabrice, Iwata, Hiroji, Ito, Yoshinori, Tsurutani, Junji, Sohn, Joohyuk, Denduluri, Neelima, Perrin, Christophe, Aogi, Kenjiro, Tokunaga, Eriko, Im, Seock-Ah, Lee, Keun Seok, Hurvitz, Sara A., Cortes, Javier, Lee, Caleb, Chen, Shuquan, Zhang, Lin, Shahidi, Javad, Yver, Antoine, Krop, Ian·2020·New England Journal of Medicine

DOI 10.1056/nejmoa1914510

Cited by (1,000)

Items 301–400 of 1,000

Glycans as Targets for Drug Delivery in Cancer
Francisca Diniz, Pedro Coelho, Henrique O. Duarte, Bruno Filipe Carmelino Cardoso Sarmento, Celso Albuquerque Reis, Joana Gomes · 2022 · Cancers
Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents
Eleni Sflakidou, George Leonidis, Eirini Foroglou, Christos Siokatas, Vasiliki Sarli · 2022 · Molecules
Incidence of antibody–drug conjugates-related pneumonitis in patients with solid tumors: A systematic review and meta-analysis
Zijun Zhu, Guoshuang Shen, Jinming Li, Tianlei Qiu, Qianqian Fang, Yonghui Zheng, Yuanfang Xin, Zhilin Liu, Fuxing Zhao, Dengfeng Ren et al. · 2023 · Critical Reviews in Oncology/Hematology
Smart Delivery Systems Responsive to Cathepsin B Activity for Cancer Treatment
Vera S. Egorova, Ekaterina P. Kolesova, Manu Lopus, Neng Yan, Alessandro Parodi, Andrey A. Zamyatnin · 2023 · Pharmaceutics
Discrimination between human epidermal growth factor receptor 2 (HER2)-low-expressing and HER2-overexpressing breast cancers: a comparative study of four MRI diffusion models
Chunping Mao, Lanxin Hu, Wei Jiang, Ya Qiu, Zehong Yang, Yeqing Liu, Mengzhu Wang, Dongye Wang, Yun Yan Su, Jinru Lin et al. · 2023 · European Radiology
HER2-Low Breast Cancer: Now and in the Future
Sora Kang, Sung‐Bae Kim · 2024 · Cancer Research and Treatment
Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies
Kexun Zhou, Xinrui Liu, Hong Zhu · 2025 · Journal of Hematology & Oncology
Toward a More Precise Future for Oncology
Murciano-Goroff, Yonina R., Taylor, Barry S., Hyman, David M., Schram, Alison M. · 2020 · Cancer Cell
Cysteine cathepsins: A long and winding road towards clinics
Monika Biasizzo, Urban Javoršek, Eva Vidak, Miki Zarić, Boris Turk · 2022 · Molecular Aspects of Medicine
Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload
Aleksei Kondrashov, Surendra Sapkota, Aditya Sharma, Ivy Riaño, Razelle Kurzrock, Jacob J. Adashek · 2023 · Pharmaceutics
Nickel-Catalyzed Antibody Bioconjugation
Vlad Bacauanu, Zoe N. Merz, Zhong L. Hua, Simon B. Lang · 2023 · Journal of the American Chemical Society
The Evolution of Antibody-Drug Conjugates: A Positive Inflexion Point
Anthony W. Tolcher · 2020 · American Society of Clinical Oncology Educational Book
Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars
Megan Elizabeth Tesch, Karen A. Gelmon · 2020 · Drugs
Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer
Francesca Ligorio, Ilaria Pellegrini, Lorenzo Castagnoli, Andrea Vingiani, Riccardo Lobefaro, Emma Zattarin, Marzia Santamaria, Serenella Maria Pupa, Giancarlo Pruneri, Filippo de Braud et al. · 2021 · Cancer Letters
Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review
Michelle Denise Hackshaw, Heather E. Danysh, Mackenzie Henderson, Eric Wang, Nora Tu, Zahidul Islam, Amy Ladner, Mary E. Ritchey, Maribel Salas · 2021 · BMC Cancer
Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer
Smruthy Sivakumar, Dexter X. Jin, Hanna Tukachinsky, Karthikeyan Murugesan, Kimberly McGregor, Natalie A. Danziger, Dean C. Pavlick, Ole V. Gjoerup, Jeffrey S. Ross, Robert Harmon et al. · 2022 · Nature Communications
The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody–drug conjugate–resistant HER2-overexpressing breast cancer
Jangsoon Lee, Kumiko Kida, Jiwon Koh, Huey Liu, Ganiraju C. Manyam, Young Jin Gi, Dileep Reddy Rampa, Asha S. Multani, Jing Wang, Gitanjali Jayachandran et al. · 2024 · Journal of Experimental & Clinical Cancer Research
Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate
Mark G. Anderson, Hugh D. Falls, Michael J. Mitten, Anatol Oleksijew, Kedar S. Vaidya, Erwin R. Boghaert, Wenqing Gao, Joann P. Palma, Diana Cao, Puey-Ling Chia et al. · 2020 · Molecular Cancer Therapeutics
Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis
Boris Itkin, A. Garcia, Samanta Straminsky, Eduardo Daniel Adelchanow, Matías G. Pereyra, Gabriela Acosta Haab, Ariel Bardach · 2021 · PLoS ONE
Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?
Sagun Parakh, Joseph A. Nicolazzo, Andrew Mark Scott, Hui Kong Gan · 2021 · Frontiers in Oncology
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study
Andrea Botticelli, Roberta Caputo, Simone Scagnoli, Simona Pisegna, Michelino De Laurentiis, Giuseppe Curigliano, Matteo Lambertini, Francesco Pantano, Antonella Palazzo, Ida Paris et al. · 2023 · The Oncologist
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
Komal L. Jhaveri, Frederik Marmé · 2023 · Cancer Treatment Reviews
Emerging Therapeutics for Patients with Triple-Negative Breast Cancer
Elisa Agostinetto, Daniel Eiger, Kevin Punie, Evandro de Azambuja · 2021 · Current Oncology Reports
Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer
Duro-Sánchez, Santiago, Nadal-Serrano, Mercedes, Lalinde-Gutiérrez, Marta, Arenas, Enrique Javier, Bernadó Morales, Cristina, Morancho, Beatriz, Escorihuela, Marta, Pérez-Ramos, Sandra, Escrivá-de-Romaní, Santiago, Gandullo-Sánchez, Lucía et al. · 2022 · Cancer Research
How I treat HER2-low advanced breast cancer
Ilana Miriam Schlam, Sara M. Tolaney, Paolo Tarantino · 2023 · The Breast
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial
Tanja Natascha Fehm, Francesco Cottone, K. Dunton, Fabrice André, Ian E. Krop, Yeon Hee Park, Michelino De Laurentiis, Yasuo Miyoshi, Anne Caroline Armstrong, Manuel Ruíz Borrego et al. · 2024 · The Lancet Oncology
Antibody–drug conjugates in breast cancer: the chemotherapy of the future?
Eleonora Nicolò, Paola Zagami, Giuseppe Curigliano · 2020 · Current Opinion in Oncology
Breast cancer management in 2021: A primer for the obstetrics and gynecology
Nicole Margo Grogan Fleege, Erin Frances Cobain · 2022 · Best Practice & Research Clinical Obstetrics & Gynaecology
HER2-Low Breast Cancer: Incidence, Clinicopathologic Features, and Survival Outcomes From Real-World Data of a Large Nationwide Cohort
Ximena Baez‐Navarro, Mieke Van Bockstal, Eleni‐Rosalina Andrinopoulou, Carolien H. M. van Deurzen · 2023 · Modern Pathology
High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a pharmacovigilance study based on the FAERS database
Pan Ma, Hao Tian, Qiuling Shi, Ruixiang Liu, Yi Zhang, Xiaowei Qi, Yongchuan Chen · 2023 · Expert Opinion on Drug Safety
A rationally designed ICAM1 antibody drug conjugate eradicates late-stage and refractory triple-negative breast tumors in vivo
Peng Guo, Jing Huang, Bing Zhu, Andrew C. Huang, Lingxiao Jiang, Jianmin Fang, Marsha A. Moses · 2023 · Science Advances
Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel
Joanne Wing Yan Chiu, Soo Chin Lee, Jcm Ho, Yeon Hee Park, Ta‐Chung Chao, Sung‐Bae Kim, Elgene Lim, Ching‐Hung Lin, Sherene Loi, Su Ying Low et al. · 2023 · Drug Safety
EGFR-directed antibodies promote HER2 ADC internalization and efficacy
Avantika Gupta, Flavia Michelini, Hong Shao, Celine Yeh, Joshua Z. Drago, Dazhi Liu, Eric Rosiek, Yevgeniy Romin, Negin Ghafourian, Sheeno P. Thyparambil et al. · 2024 · Cell Reports Medicine
NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer
Sara Santana-Hernández, Jesús Suárez-Olmos, Sònia Servitja, Pau Berenguer‐Molins, Marcel Costa-García, Laura Comerma, Anna Rea, Júlia Perera‐Bel, Sílvia Menéndez, Oriol Arpí et al. · 2024 · Journal of Experimental & Clinical Cancer Research
Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial
Masataka Yagisawa, Hiroya Taniguchi, Taroh Satoh, Shigenori Kadowaki, Yu Sunakawa, Tomohiro Nishina, Yoshito Komatsu, Taito Esaki, Daisuke Sakai, Ayako Doi et al. · 2024 · Journal of Clinical Oncology
HER2-low gastric cancer: is the subgroup targetable?
Keitaro Shimozaki, Shota Fukuoka, Akira Ooki, Kensei Yamaguchi · 2024 · ESMO Open
HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future
Luying Xu, Yuxin Xie, Qiheng Gou, Rui Cai, Rong Bao, Yucheng Huang, Ruisi Tang · 2024 · Frontiers in Pharmacology
New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?
Essia Mezni, Cécile Vicier, Mathilde Guérin, Renaud Sabatier, François Bertucci, Anthony Gonçalvès · 2020 · Cancers
Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes
Timothy Anthony Yap, Erika Hamilton, Todd Michael Bauer, Ecaterina E. Dumbrava, Rinath Jeselsohn, Aaron Enke, Sabrina Hurley, Kevin K. Lin, Jenn Habeck, Heidi Giordano et al. · 2022 · JCO Precision Oncology
HER2 targeted therapy in colorectal cancer: New horizons
Ali Abdulnabi Suwaidan, David K. Lau, Ian Chau · 2022 · Cancer Treatment Reviews
Phase I clinical evaluation of 99m Tc-labeled Affibody molecule for imaging HER2 expression in breast cancer
Olga Bragina, Владимир Иванович Чернов, Мария Сергеевна Ларькина, Anstasiya Rybina, Roman Zelchan, Е. Yu. Garbukov, Maryam Oroujeni, Annika Loftenius, Anna Orlova, Jens Sörensen et al. · 2023 · Theranostics
Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice
Ling Zhou, Yunlong Lu, Wei Liu, Shanglong Wang, Lingling Wang, Pengdou Zheng, Guisha Zi, Huiguo Liu, Wukun Liu, Shuang Wei · 2024 · Experimental Hematology and Oncology
Disseminated cancer cells in breast cancer: Mechanism of dissemination and dormancy and emerging insights on therapeutic opportunities
Ganesan Ramamoorthi, Krithika Nandakumar Kodumudi, Corey Gallen, Nadia Nocera Zachariah, Amrita B Basu, Gabriella K. Albert, Amber Beyer, Colin Snyder, Doris A. Wiener, Ricardo Lima Barros Costa et al. · 2021 · Seminars in Cancer Biology
Review of the status of neoadjuvant therapy in HER2-positive breast cancer
Gavin Paul Dowling, Stephen Keelan, Sinéad Toomey, Gordon Richard Daly, Bryan T. Hennessy, Arnold D. K. Hill · 2023 · Frontiers in Oncology
Landscape of combination therapy trials in breast cancer brain metastasis
Jawad Fares, Deepak Kanojia, Aida Rashidi, Ilya V. Ulasov, Maciej S. Lesniak · 2020 · International Journal of Cancer
The emerging role of antibody-drug conjugates in urothelial carcinoma
Michael William Lattanzi, Jonathan E. Rosenberg · 2020 · Expert Review of Anticancer Therapy
Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody–Drug Conjugates to Increase In Vivo Efficacy
Jose F. Ponte, Leanne Lanieri, Eshita Khera, Rassol Laleau, Olga Ab, Christopher W. Espelin, Neeraj Kohli, Bahar Matin, Yulius Y. Setiady, Michael L. Miller et al. · 2020 · Molecular Cancer Therapeutics
Extracellular vesicles as modifiers of antibody‐drug conjugate efficacy
Márk Barok, Maija Puhka, Narjes Yazdi, Heikki Joensuu · 2021 · Journal of Extracellular Vesicles
Mesoporous silica nanoparticle: Heralding a brighter future in cancer nanomedicine
Milad Abbasi, Salar Hafez Ghoran, Mohammad Hadi Niakan, Kazem Jamali, Zohre Moeini, Ali Jangjou, Peyman Izadpanah, Ali Mohammad Amani · 2021 · Microporous and Mesoporous Materials
Aiming at a Tailored Cure for ERBB2 -Positive Metastatic Breast Cancer
Paolo Tarantino, Giuseppe Curigliano, Heather A. Parsons, NU Lin, Ian E. Krop, Elizabeth A. Mittendorf, Adrienne Gropper Waks, Eric P. Winer, Sara M. Tolaney · 2022 · JAMA Oncology
Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist’s Perspective
Lucas, Andrew T., Moody, Amber, Schorzman, Allison N., Zamboni, William C. · 2021 · Antibodies
Combining nanotechnology with monoclonal antibody drugs for rheumatoid arthritis treatments
Xiao-Kai Chi, Xiaoling Xu, Bang-Yao Chen, Jin Yang Su, Yongzhong Du · 2023 · Journal of Nanobiotechnology
Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective
Jan‐Willem Henning, Christine Brezden‐Masley, Karen A. Gelmon, Stephen Chia, Shane Shapera, Micheal Chad McInnis, Daniel Rayson, Jamil Asselah · 2023 · Current Oncology
Small-molecule inhibitors of kinases in breast cancer therapy: recent advances, opportunities, and challenges
Isha Bansal, Amit Kumar Pandey, Munindra Ruwali · 2023 · Frontiers in Pharmacology
Ocular adverse events associated with antibody-drug conjugates for cancer: evidence and management strategies
Grace Kho Dy, Asim V. Farooq, Joann J. Kang · 2024 · The Oncologist
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)
Nicholas C. Turner, Cristina Saura, Philippe Georges Aftimos, Evelyn van den Tweel, M. Oesterholt, N.P. Koper, Marco Angelo Colleoni, Emilie Kaczmarek, Kevin Punie, Xinni Song et al. · 2024 · Journal of Clinical Oncology
Unveiling the future of breast cancer therapy: Cutting-edge antibody-drug conjugate strategies and clinical outcomes
Lu Sun, Xiaomeng Jia, Kainan Wang, Man Li · 2024 · The Breast
Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond
José Manuel Pérez-García, Laia Garrigós, María Gión, Pasi Antero Janne, Kohei Shitara, Salvatore Siena, Javier Cortés · 2021 · Expert Opinion on Biological Therapy
Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis
Mikiko Suzuki, Shigehiro Yagishita, Kiyoshi Sugihara, Yusuke Ogitani, Tadaaki Nishikawa, Mayu Ohuchi, Takashi Teishikata, Takahiro Jikoh, Yasushi Yatabe, Kan Yonemori et al. · 2021 · Clinical Cancer Research
CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer
Lubaid Saleh, Caroline Wilson, Ingunn Holen · 2021 · MedComm
Antibody-drug conjugates in HER2-positive breast cancer
Lixi Li, Di Zhang, Binliang Liu, Dan Lv, Jingtong Zhai, Xiuwen Guan, Zongbi Yi, Fei Ma · 2021 · Chinese Medical Journal
Antibody drug conjugates in non-small cell lung cancer: An emerging therapeutic approach
S Marks, Jarushka Naidoo · 2021 · Lung Cancer
Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis
Youwen Zhu, Kun Liu, Min Wang, Kailing Wang, Hong Zhu · 2022 · The Breast
Management of Early-Stage Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Sònia Pernas, Sara M. Tolaney · 2021 · JCO Oncology Practice
Safety of trastuzumab deruxtecan: A meta‐analysis and pharmacovigilance study
Zihan Guo, Yunlan Ding, Mengmeng Wang, Jiyong Liu, Qing Zhai, Qiong Du · 2022 · Journal of Clinical Pharmacy and Therapeutics
De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial
Nadia Harbeck, Ulrike Anneliese Nitz, Matthias Christgen, Sherko Kümmel, Michael Braun, Claudia Schumacher, Jochem Potenberg, Joke Tio, Bahriye Aktas, Helmut Forstbauer et al. · 2023 · Journal of Clinical Oncology
Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs)
Bruna Scheuher, Khem Raj Ghusinga, Kimiko McGirr, Maksymilian Nowak, Sheetal Panday, Joshua F. Apgar, Kalyanasundaram Subramanian, Alison M. Betts · 2023 · Journal of Pharmacokinetics and Pharmacodynamics
HER2 splice variants in breast cancer: investigating their impact on diagnosis and treatment outcomes
Vic Hart, Hannah Gautrey, John Andrew Kirby, Alison Jane Tyson-Capper · 2020 · Oncotarget
Identification of cell surface targets for CAR-T cell therapies and antibody–drug conjugates in breast cancer
Francesco Schettini, Paula Barbao, Fara Brasó‐Maristany, Patricia Galván, D. Martínez, Laia Paré, Sabino De Placido, Aleix Prat, Sònia Guedan · 2021 · ESMO Open
Sacituzumab Govitecan: Past, Present and Future of a New Antibody–Drug Conjugate and Future Horizon
Jenny Furlanetto, Frederik Marmé, Sibylle Loibl · 2022 · Future Oncology
Development and Validation of MRI Radiomics Models to Differentiate HER2-Zero, -Low, and -Positive Breast Cancer
Yuqin Peng, Xiang Zhang, Ya Qiu, Baoxun Li, Zehong Yang, Jiayi Huang, Jinru Lin, Chushan Zheng, Lanxin Hu, Jun Shen · 2024 · American Journal of Roentgenology
Impact of concurrent antibody–drug conjugates and radiotherapy on symptomatic radiation necrosis in breast cancer patients with brain metastases: a multicenter retrospective study
Yutaro Koide, Naoya Nagai, Sou Adachi, Masayuki Ito, Mariko Kawamura, Makoto Ito, Fumitaka Ito, Yurika Shindo, Takahiro Aoyama, Hidetoshi Shimizu et al. · 2024 · Journal of Neuro-Oncology
Influence of antibody–drug conjugate cleavability, drug-to-antibody ratio, and free payload concentration on systemic toxicities: A systematic review and meta-analysis
Shou‐Ching Tang, Carrie Wynn, Tran Le, Martin G. McCandless, Yunxi Zhang, Ritesh Patel, Nita J. Maihle, William B. Hillegass · 2024 · Cancer and Metastasis Reviews
B-Cell Epitope Peptide Cancer Vaccines: A New Paradigm for Combination Immunotherapies with Novel Checkpoint Peptide Vaccine
Pravin T. P. Kaumaya · 2020 · Future Oncology
Leptomeningeal Metastases: New Opportunities in the Modern Era
Jessica A. Wilcox, Minjun Li, Adrienne Ann Boire · 2022 · Neurotherapeutics
Structure–Activity Relationships of Antibody-Drug Conjugates: A Systematic Review of Chemistry on the Trastuzumab Scaffold
Siddharth S. Matikonda, Ryan McLaughlin, Pradeep Shrestha, Carol Lipshultz, Martin J. Schnermann · 2022 · Bioconjugate Chemistry
Molecular perspective on targeted therapy in breast cancer: a review of current status
Busra Demir Cetinkaya, Çığır Biray Avcı · 2022 · Medical Oncology
Current landscape of personalized clinical treatments for triple-negative breast cancer
Jun Zhang, Yu Xia, Xiaomei Zhou, Honghao Yu, Yufang Tan, Yaying Du, Qi Zhang, Yiping Wu · 2022 · Frontiers in Pharmacology
Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma
Wang, Yifei, Tian, Xiangjun, Zhang, Wendong, Zhang, Zhongting, Lazcano, Rossana, Hingorani, Pooja, Roth, Michael E., Gill, Jonathan D., Harrison, Douglas J., Xu, Zhaohui et al. · 2022 · Molecular Cancer Therapeutics
Efficacy and Safety of Trastuzumab Deruxtecan in Breast Cancer: A Systematic Review and Meta-Analysis
Gavin Paul Dowling, Gordon Richard Daly, Stephen Keelan, Fiona Boland, Sinéad Toomey, Arnold D. K. Hill, Bryan T. Hennessy · 2023 · Clinical Breast Cancer
Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models
Hirokazu Suzuki, Shotaro Nagase, Chiemi Saito, Atsuko Takatsuka, Motoko Nagata, Kokichi Honda, Yuki Kaneda, Yumi Nishiya, Tomoyo Honda, Tomomichi Ishizaka et al. · 2024 · Molecular Cancer Therapeutics
Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer
Ashenafi Shiferaw Bulle, Peng Liu, Kuljeet Seehra, Sapana Bansod, Yali Chen, Kiran Zahra, Vikas Somani, Iftikhar Ali Khawar, Hung-Po Chen, Paarth B. Dodhiawala et al. · 2024 · Nature Communications
Emerging importance of HER3 in tumorigenesis and cancer therapy
Joan T. Garrett, Salomon Tendler, Wasim Feroz, Mary Kate Kilroy, Helena Alexandra Yu · 2025 · Nature Reviews Clinical Oncology
HER2 antibody-drug conjugate controls growth of breast cancer brain metastases in hematogenous xenograft models, with heterogeneous blood–tumor barrier penetration unlinked to a passive marker
Brunilde Gril, Debbie Wei, Alexandra S. Zimmer, Christina M. Robinson, Imran Khan, Simone Difilippantonio, Michael Glen Overstreet, Patricia Schriver Steeg · 2020 · Neuro-Oncology
Anti‐EGFR antibody‐drug conjugate for triple‐negative breast cancer therapy
Yingnan Si, Yuanxin Xu, Jia-Shiung Guan, Kai Chen, Seulhee Kim, Eddy Shih-Hsin Yang, Lufang Zhou, Margaret Liu · 2020 · Engineering in Life Sciences
Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature
Eirini Thanopoulou, Leila Khader, Morena Caira, Andrew M. Wardley, Johannes Ettl, Federica Miglietta, Patrick Neven, Valentina Guarneri · 2020 · Cancers
Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics
Gail D. Lewis Phillips, Jun Guo, James R. Kiefer, William R. Proctor, Daniela Bumbaca Yadav, Noel O. Dybdal, Ben‐Quan Shen · 2021 · Breast Cancer Research and Treatment
FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer
Melanie Royce, Christy L. Osgood, Anup K. Amatya, Mallorie H. Fiero, C.J. George Chang, Tiffany K. Ricks, Krithika A. Shetty, Jeffrey B. Kraft, Junshan Qiu, Pengfei Song et al. · 2021 · Clinical Cancer Research
Emerging treatment strategies for metastatic triple-negative breast cancer
Laura Ann Huppert, Özge Gümüşay, Hope S. Rugo · 2022 · Therapeutic Advances in Medical Oncology
Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management of Selected Adverse Events Associated with Trastuzumab Deruxtecan
Aditya Bardia, Kathleen Kiernan Harnden, Lauren Ann Mauro, Angela Pennisi, Melissa Armitage, Hatem Hussein Soliman · 2022 · The Oncologist
Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy
Chi Hun Song, Minchan Jeong, Hyukmin In, Ji Hoe Kim, Chih‐Wei Lin, Kyung Ho Han · 2023 · Antibodies
Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer
Khalil Saleh, Rita Khoury, Nadine Khalife, Claude Chahine, Rebecca Ibrahim, Zamzam Tikriti, Axel Le Cesne · 2024 · Cancer Drug Resistance
Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial
Marta Vaz Batista, José Manuel Pérez-García, Patricia Cortez, Laia Garrigós, María Fernández-Abad, María Gión, A. Martinez Bueno, Cristina Saavedra, Iris Teruel, Adela Fernández-Ortega et al. · 2024 · ESMO Open
Challenges and prospects in HER2-positive breast cancer-targeted therapy
Xi‐Yin Li, Xueying Zhang, Saige Yin, Jianyun Nie · 2025 · Critical Reviews in Oncology/Hematology
On the use of DNA as a linker in antibody-drug conjugates: synthesis, stability and in vitro potency
Igor Dovgan, Anthony Ehkirch, Victor Lehot, Isabelle Kuhn, Oleksandr Koniev, Sergii Kolodych, Alexandre Hentz, Manon Ripoll, Sylvain Ursuegui, Marc Nothisen et al. · 2020 · Scientific Reports
Diagnostic and Therapeutic Updates in Leptomeningeal Disease
Meaghan A. Roy-O’Reilly, Tyler Ashford Lanman, Amber Nicole Ruiz, David S. Rogawski, Brian R. Stocksdale, Seema Nagpal · 2023 · Current Oncology Reports
A Cancer-Specific Monoclonal Antibody against HER2 Exerts Antitumor Activities in Human Breast Cancer Xenograft Models
Mika Kato Kaneko, Hiroyuki Suzuki, Tomokazu Ohishi, Takuro Nakamura, Tomohiro Tanaka, Yukinari Kato · 2024 · International Journal of Molecular Sciences
The Evolution of Antibody‐Drug Conjugates: Toward Accurate DAR and Multi‐specificity
Wenge Dong, Wanqi Wang, Chan Cao · 2024 · ChemMedChem
Targeted drug conjugates in cancer therapy: Challenges and opportunities
Geng Jia, Yuqi Jiang, Xiaoyang Li · 2024 · Pharmaceutical Science Advances
Antibody–bottlebrush prodrug conjugates for targeted cancer therapy
Bin Liu, Hung V.‐T. Nguyen, Yivan Jiang, Aiden Wang, Valerie Lensch, Zehao Sun, Zane Boyer, Philip A Raftopoulos, Yutong Dai, Piper L. MacNicol et al. · 2025 · Nature Biotechnology